Anti-sulfatide antibodies in neurological disorders: should we test?
Anti-sulfatide antibodies
Autoimmune
Neurological disorders
Sulfatide
Journal
Journal of neurology
ISSN: 1432-1459
Titre abrégé: J Neurol
Pays: Germany
ID NLM: 0423161
Informations de publication
Date de publication:
03 Sep 2024
03 Sep 2024
Historique:
received:
03
07
2024
accepted:
26
08
2024
revised:
09
08
2024
medline:
3
9
2024
pubmed:
3
9
2024
entrez:
3
9
2024
Statut:
aheadofprint
Résumé
Neurological autoimmune peripheral and central nervous system disorders can be associated with anti-sulfatide antibodies. These antibodies are considered potential diagnostic biomarkers, although their additional diagnostic value in neurological fields has been increasingly questioned. Given the little evidence of anti-sulfatide antibodies' frequency and diagnostic value in neurology, we aimed to fill this knowledge gap by investigating 10 years of data. This retrospective study analyzed the results of the anti-ganglioside dot kits (GA Generic Assays GmbH) from 1318 serum samples and 462 cerebrospinal fluid (CSF) samples for the frequency, sensitivity, and specificity of anti-sulfatide antibodies in neurological disorders. Although anti-sulfatide antibodies are rarely present in neurological autoimmune disorders (serum IgM 2.5%, IgG 4.6%), they are also present in non-autoimmune diseases (serum IgM 1.2%, IgG 2.5%) and lack sensitivity and specificity towards being a diagnostic marker. Furthermore, anti-sulfatide antibodies are rarely found in CSF (e.g., no positive results for IgM), and including so-called borderline results ((+)) increases sensitivity and the false-positive rate in serum and CSF. While anti-sulfatide antibodies appear more frequently in neurological autoimmune diseases, they are rare overall and provide very limited diagnostic value in determining specific neurological diseases and-more importantly-if a neurological disease has a potential autoimmune etiology.
Identifiants
pubmed: 39225745
doi: 10.1007/s00415-024-12668-8
pii: 10.1007/s00415-024-12668-8
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Medizinischen Fakultät, Eberhard Karls Universität Tübingen
ID : 3037-0-0
Organisme : Medizinischen Fakultät, Eberhard Karls Universität Tübingen
ID : 45800
Informations de copyright
© 2024. The Author(s).
Références
Carpo M, Meucci N, Allaria S, Marmiroli P, Monaco S, Toscano A, Simonetti S, Scarlato G, Nobile-Orazio E (2000) Anti-sulfatide IgM antibodies in peripheral neuropathy. J Neurol Sci 176:144–150. https://doi.org/10.1016/S0022-510X(00)00342-7
doi: 10.1016/S0022-510X(00)00342-7
pubmed: 10930598
Cavazzana I, Fredi M, Ceribelli A, Mordenti C, Ferrari F, Carabellese N, Tincani A, Satoh M, Franceschini F (2016) Testing for myositis specific autoantibodies: comparison between line blot and immunoprecipitation assays in 57 myositis sera. J Immunol Methods 433:1–5. https://doi.org/10.1016/j.jim.2016.02.017
doi: 10.1016/j.jim.2016.02.017
pubmed: 26906088
Cavazzana I, Richards M, Bentow C, Seaman A, Fredi M, Giudizi MG, Palterer B, Pratesi F, Migliorini P, Franceschini F, Satoh M, Ceribelli A, Mahler M (2019) Evaluation of a novel particle-based assay for detection of autoantibodies in idiopathic inflammatory myopathies. J Immunol Methods 474:112661. https://doi.org/10.1016/j.jim.2019.112661
doi: 10.1016/j.jim.2019.112661
pubmed: 31442464
Farah MH, Dali C, Groeschel S, Moldovan M, Whiteman DAH, Malanga CJ, Krägeloh-Mann I, Li J, Barton N, Krarup C (2024) Effects of sulfatide on peripheral nerves in metachromatic leukodystrophy. Ann Clin Transl Neurol 11:328–341. https://doi.org/10.1002/acn3.51954
doi: 10.1002/acn3.51954
pubmed: 38146590
Fehmi J, Vale T, Keddie S, Rinaldi S (2021) Nodal and paranodal antibody-associated neuropathies. Pract Neurol. https://doi.org/10.1136/practneurol-2021-002960
doi: 10.1136/practneurol-2021-002960
pubmed: 34039750
Giannotta C, Di Pietro D, Gallia F, Nobile-Orazio E (2015) Anti-sulfatide IgM antibodies in peripheral neuropathy: to test or not to test? Eur J Neurol 22:879–882. https://doi.org/10.1111/ene.12658
doi: 10.1111/ene.12658
pubmed: 25597226
Giesche N, Böhm-Gonzalez ST, Kleiser B, Kowarik MC, Dubois E, Stransky E, Armbruster M, Grimm A, Marquetand J (2024) Antiganglioside antibody frequency in routine clinical care settings. Eur J Neurol 31:e16290. https://doi.org/10.1111/ene.16290
doi: 10.1111/ene.16290
pubmed: 38556758
pmcid: 11236029
Hirahara Y, Wakabayashi T, Mori T, Koike T, Yao I, Tsuda M, Honke K, Gotoh H, Ono K, Yamada H (2017) Sulfatide species with various fatty acid chains in oligodendrocytes at different developmental stages determined by imaging mass spectrometry. J Neurochem 140:435–450. https://doi.org/10.1111/jnc.13897
doi: 10.1111/jnc.13897
pubmed: 27861899
Ilyas AA, Chen ZW, Cook SD (2003) Antibodies to sulfatide in cerebrospinal fluid of patients with multiple sclerosis. J Neuroimmunol 139:76–80. https://doi.org/10.1016/s0165-5728(03)00131-0
doi: 10.1016/s0165-5728(03)00131-0
pubmed: 12799023
Isoardo G, Ferrero B, Barbero P, Cucci A, Oggero A, Pipieri A, Ricci A, Verdun E, Bergamasco B, Durelli L (2001) Anti-GM1 and anti-sulfatide antibodies in polyneuropathies. Threshold titers and accuracy. Acta Neurol Scand 103:180–187. https://doi.org/10.1034/j.1600-0404.2001.103003180.x
doi: 10.1034/j.1600-0404.2001.103003180.x
pubmed: 11240566
Kanter JL, Narayana S, Ho PP, Catz I, Warren KG, Sobel RA, Steinman L, Robinson WH (2006) Lipid microarrays identify key mediators of autoimmune brain inflammation. Nat Med 12:138–143. https://doi.org/10.1038/nm1344
doi: 10.1038/nm1344
pubmed: 16341241
Meehan GR, McGonigal R, Cunningham ME, Wang Y, Barrie JA, Halstead SK, Gourlay D, Yao D, Willison HJ (2018) Differential binding patterns of anti-sulfatide antibodies to glial membranes. J Neuroimmunol 323:28–35. https://doi.org/10.1016/j.jneuroim.2018.07.004
doi: 10.1016/j.jneuroim.2018.07.004
pubmed: 30196830
pmcid: 6134133
Novakova L, Henricsson M, Björnson E, Axelsson M, Borén J, Rosenstein I, Lycke J, Cardell SL, Blomqvist M (2023) Cerebrospinal fluid sulfatide isoforms lack diagnostic utility in separating progressive from relapsing-remitting multiple sclerosis. Mult Scler Relat Disord 74:104705. https://doi.org/10.1016/j.msard.2023.104705
doi: 10.1016/j.msard.2023.104705
pubmed: 37060853
Pestronk A, Li F, Griffin J, Feldman EL, Cornblath D, Trotter J, Zhu S, Yee WC, Phillips D, Peeples DM et al (1991) Polyneuropathy syndromes associated with serum antibodies to sulfatide and myelin-associated glycoprotein. Neurology 41:357–362. https://doi.org/10.1212/wnl.41.3.357
doi: 10.1212/wnl.41.3.357
pubmed: 1706491
To F, Ventín-Rodríguez C, Elkhalifa S, Lilleker JB, Chinoy H (2020) Line blot immunoassays in idiopathic inflammatory myopathies: retrospective review of diagnostic accuracy and factors predicting true positive results. BMC Rheumatol 4:28. https://doi.org/10.1186/s41927-020-00132-9
doi: 10.1186/s41927-020-00132-9
pubmed: 32699830
pmcid: 7370419